logo
This Artificial Intelligence (AI) Stock Isn't in Warren Buffett's Portfolio -- but It Follows His Rules

This Artificial Intelligence (AI) Stock Isn't in Warren Buffett's Portfolio -- but It Follows His Rules

Globe and Mail6 hours ago

In May, Warren Buffett announced that he plans to step down from his role as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) at the end of 2025. It will cap off a spectacular run of success that dates back to 1965 -- though his journey isn't over completely, because he will continue to serve as chairman of Berkshire's board.
Had you invested $1,000 in Berkshire stock when Buffett took the helm 60 years ago and held on for that entire time, you'd have been sitting on shares worth an eye-popping $44.7 million at the end of 2024. The same investment in the S&P 500 (SNPINDEX: ^GSPC) index would have grown to just $342,906 over the same period. Part of that growth came from the dozens of businesses that the conglomerate purchased in their entirety over the years, but the rest was driven by the incredible stock-picking of Buffett and his team.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Buffett uses a simple strategy, and as a general rule, he tends to avoid buying shares of companies whose businesses he doesn't understand. As a result, he doesn't invest in technology stocks very often, and he certainly doesn't chase hot trends like artificial intelligence (AI).
However, there is one AI stock that could be a great fit in Berkshire's portfolio because it meets most of Buffett's investment criteria, and he has even expressed regret for not investing in it during its early years.
Warren Buffett uses a simple investing strategy
Buffett is a value investor who likes to buy good companies when they are trading cheap, but he doesn't shy away from picking up shares of spectacular companies at a fair price.
When considering a potential investment, Buffett looks for companies with steady growth, reliable profitability, and strong management teams. He also likes companies that return money to shareholders through dividends and stock buyback programs. But time is Buffett's most important weapon because compound growth amplifies his results over the long term -- he has often been quoted as saying his preferred holding period is forever.
Buffett oversees numerous wholly owned Berkshire Hathaway subsidiaries, including Duracell, Dairy Queen, and GEICO Insurance. But he also helps manage its portfolio of publicly traded stocks and securities, which currently includes holdings in 38 companies and is worth around $278 billion today. As I mentioned earlier, he generally avoids technology stocks like those in the " Magnificent Seven," but he has made exceptions.
Between 2016 and 2023, Buffett plowed approximately $38 billion into Apple, which was the most money Berkshire had ever invested in any single company. He views Apple as a consumer products company rather than a tech company, and he often commends the strength of its brand. Plus, the iPhone maker repurchased more than $100 billion worth of its own stock in the past year alone, and it also pays a modest dividend.
Berkshire also has a small $2.1 billion position in another Magnificent Seven name: Amazon. Though it has a track record of growing its top and bottom lines nicely, Amazon isn't the perfect Buffett stock because the company doesn't pay a dividend, and it hasn't executed any buybacks since 2022. Plus, the stock isn't exactly cheap.
Alphabet ticks most of Buffett's boxes
Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) is another Magnificent Seven technology stock that could be a great fit for Berkshire Hathaway's portfolio. It's the parent company of Google, YouTube, Waymo, and more, and it has most of the qualities Buffett normally looks for in an investment.
First, Alphabet has a spectacular long-term track record of growing its revenue and earnings per share (EPS).
Data by YCharts.
Second, Alphabet is returning significant sums of money to shareholders. Over the last four quarters alone, it distributed $9.8 billion in dividends and completed more than $61 billion worth of share buybacks.
Data by YCharts.
Third, Alphabet has a strong and stable management team led by Sundar Pichai, who joined the company in 2004 and has served as its CEO since 2015. Plus, Google co-founders Larry Page and Sergey Brin are still on Alphabet's board to ensure the company continues to head in the right direction.
The fourth and final reason Alphabet might be a good fit for Berkshire's portfolio is its valuation. The stock is trading at a price-to-earnings (P/E) ratio of just 19.4, which is cheaper than the broader market based on the 23.7 P/E ratio of the S&P 500 index. Plus, it's the cheapest Magnificent Seven stock by far.
Data by YCharts.
While Berkshire has never owned Alphabet stock, Buffett has definitely thought about it. In fact, during an interview back in 2017, he said his reluctance to invest during the company's earlier years was a mistake.
Alphabet faces some challenges, but it's already a leader in AI
Alphabet generates more than half of its revenue from selling advertising space to businesses adjacent to Google Search results, but that business is facing disruption from two angles. First, the U.S. Department of Justice recently won a court case against it over its anticompetitive behaviors. The end result of that case could be that Alphabet gets compelled to stop paying billions of dollars a year to Apple to make Google the default search engine on the browsers installed on devices like the iPhone.
The judge in the case has yet to hand down his ruling on penalties and remedies, and the company will certainly appeal his decision, but any result that erodes Google's 89.5% market share in the internet search industry could deal a blow to Alphabet's financial results, which might be one of the reasons its stock is so cheap right now.
The second challenge is AI. Chatbots like OpenAI's ChatGPT can provide direct answers to almost any query, whereas traditional search engines may point the user in the right direction, but still require them to sift through web pages to find the information they need. Alphabet is combating this threat with AI Overviews, which are AI-generated answers that appear above the traditional results in Google Search. The company hopes this will stop users from abandoning its search engine in favor of chatbots.
However, Alphabet hedged its bets by launching its own AI assistant, Gemini. It isn't just a stand-alone chatbot, because Alphabet also embedded it into Google Workspace applications like Gmail, Docs, and Sheets. This should reduce users' interest in venturing outside the Google ecosystem to find information from competitors like OpenAI.
In summary, Alphabet has become one of the clear leaders in AI, and that should help insulate it from potential disruption. However, investors like Buffett might feel the company's future is too uncertain to buy the stock with conviction. On the other hand, I think its cheap valuation offers sufficient compensation for the known risks.
Should you invest $1,000 in Alphabet right now?
Before you buy stock in Alphabet, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!*
Now, it's worth noting Stock Advisor 's total average return is791% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Berkshire Hathaway, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ISRG vs BSX: Which Medical Device Stock Has More Room to Run?
ISRG vs BSX: Which Medical Device Stock Has More Room to Run?

Globe and Mail

time32 minutes ago

  • Globe and Mail

ISRG vs BSX: Which Medical Device Stock Has More Room to Run?

In a healthcare landscape increasingly shaped by technology, two names that stand out for their innovation and long-term potential are Intuitive Surgical ISRG and Boston Scientific BSX. Both companies are at the forefront of minimally invasive procedures — Intuitive as the undisputed leader in robotic-assisted surgery, and Boston Scientific as a powerhouse in interventional medical devices. With growing demand for advanced surgical solutions and aging global populations driving healthcare needs, investors are eyeing these med-tech giants as attractive long-term plays. But, which stock offers more compelling upside right now? Let's break down the fundamentals, growth trajectories, and market positions of ISRG and BSX to find out which one deserves a place in your portfolio. ISRG & BSX: Price Performance Intuitive Surgical represents a high-growth, high-premium pure play on robotic-assisted surgery. Its exceptional performance and growth provide compelling upside, but investors must accept margin compression and valuation risk in the short-to-medium term. Boston Scientific offers broader exposure to medical device innovation, with reliable growth driven by cardiovascular and interventional segments. It trades at a more moderate valuation and may appeal to investors seeking growth with less volatility. The year-to-date price performance of Intuitive Surgical has not been impressive, likely due to tariff concerns and rising competition from Chinese robotic device makers. However, BSX has outperformed ISRG likely due to its diversified business as well as strong U.S. demand. Shares of ISRG have lost 1.9% year to date, while those of BSX have gained 13.9%. Market Position & Core Offerings Intuitive Surgical dominates the surgical robotics niche with its flagship da???Vinci system, which continues to gain traction globally — 367 new units placed in the first quarter of 2025 alone, leading to a 17% year-over-year increase in procedures. Boston Scientific, by contrast, operates across a broader landscape of interventional medical devices, from cardiovascular to neuromodulation. Its success with Farapulse pulsed field ablation and strong cardiovascular sales (+26% in first-quarter 2025) highlight its diversified growth drivers. Growth & Performance ISRG delivered robust first-quarter 2025 results: revenues grew 19% to $2.25 billion, adjusted net income rose 22% to $767.5 million, and adjusted EPS grew 21% to $1.81. Its projected procedure growth remains strong at 15-17% for the year, though margins may be pressured by tariffs. BSX also posted solid first-quarter 2025 earnings, with adjusted EPS of $0.75 and sales worth $4.66 billion, both beating expectations on the back of cardiovascular and medical-surgical divisions. For the second quarter of 2025, revenues are expected to grow by double digits, driven by PFA and other interventions. Estimates Comparison for ISRG & BSX The Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 6.8%, respectively. EPS estimates for 2025 and 2026 have trended southward over the past 60 days. ISRG Estimate Movement The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. Moreover, EPS estimates for 2025 and 2026 have improved over the past 60 days. BSX Estimate Movement Cash & Cash Flow Intuitive Surgical maintains an exceptionally strong balance sheet, with $4.51 billion in cash and no debt as of the first quarter of 2025. The company generated free cash flow of around $465 million and operating cash flow of $582 million, driven by continued growth in da Vinci system procedures and high-margin recurring revenues from instruments and accessories. Boston Scientific, operates with a more leveraged profile. The company reported $725 million in cash and $11.31 billion in total debt, with a debt-to-equity ratio of nearly 50%. Despite this, BSX maintains strong cash generation, posting $541 million in operating cash flow and $354 million in free cash flow for the first quarter of 2025 alone. Its diversified product base, especially in cardiovascular and electrophysiology, supports ongoing growth and debt service. Risks & Operational Challenges ISRG is exposed to geopolitical and trade-related tariff risks — especially a 125% tariff on Chinese exports — which have led to margin revisions for 2025. Mitigation efforts include supply-chain adjustments and pricing flexibility. BSX contends with regulatory and legal exposures (notably from past medical-device recalls and mesh product lawsuits), but its diversified supply chain and global footprint help buffer macroeconomic pressures. ISRG or BSX: Which Is a Better Bet? For investors focused on explosive, category-leading growth in surgical robotics, ISRG may still be the superior choice. But those who prefer balanced exposure across med-tech segments with a steadier valuation profile might consider BSX as a more diversified, resilient option. Intuitive Surgical stands out for its pristine balance sheet, zero debt, and strong free cash flow, making it an appealing choice for investors prioritizing financial stability and growth. Boston Scientific's leveraged balance sheet is offset by a diversified product base and solid, consistent cash generation, positioning it as a resilient and innovative med-tech player for investors comfortable with moderate financial risk. Both companies currently carry a Zacks Rank #3 (Hold). However, if we go by the Zacks Style Score, BSX seems to be a better bet compared to ISRG. While ISRG has a Zacks Style Score of 'D', BSX's score is 'C', reflecting better growth potential. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

Amazon CEO Jassy says AI will reduce its corporate workforce in the next few years
Amazon CEO Jassy says AI will reduce its corporate workforce in the next few years

CTV News

time36 minutes ago

  • CTV News

Amazon CEO Jassy says AI will reduce its corporate workforce in the next few years

Andy Jassy, Amazon president and CEO, attends the premiere of "The Lord of the Rings: The Rings of Power" at The Culver Studios on Monday, Aug. 15, 2022, in Culver City, Calif parts of its business, shuttering stores and slashing 29,000 jobs in an effort to reduce costs. (Photo by Jordan Strauss/Invision/AP, File) Amazon CEO Andy Jassy anticipates generative artificial intelligence will reduce its corporate workforce in the next few years as the online giant begins to increase its usage of the technology. 'We will need fewer people doing some of the jobs that are being done today, and more people doing other types of jobs,' Jassy said in a message to employees. 'It's hard to know exactly where this nets out over time, but in the next few years, we expect that this will reduce our total corporate workforce as we get efficiency gains from using AI extensively across the company.' The executive said that Amazon has more than 1,000 generative AI services and applications in progress or built, but that figure is a 'small fraction' of what it plans to build. Jassy encouraged employees to get on board with the e-commerce company's AI plans. 'As we go through this transformation together, be curious about AI, educate yourself, attend workshops and take trainings, use and experiment with AI whenever you can, participate in your team's brainstorms to figure out how to invent for our customers more quickly and expansively, and how to get more done with scrappier teams,' he said. Earlier this month Amazon announced that it was planning to invest $10 billion toward building a campus in North Carolina to expand its cloud computing and artificial intelligence infrastructure. Since 2024 started, Amazon has committed to about $10 billion apiece to data center projects in Mississippi, Indiana, Ohio and North Carolina as it ramps up its infrastructure to compete with other tech giants to meet growing demand for artificial intelligence products. The rapid growth of cloud computing and artificial intelligence has meanwhile fueled demand for energy-hungry data centers that need power to run servers, storage systems, networking equipment and cooling systems. Amazon said earlier this month that it will spend $20 billion on two data center complexes in Pennsylvania. In March Amazon began testing artificial intelligence-aided dubbing for select movies and shows offered on its Prime streaming service. A month earlier, the company rolled out a generative-AI infused Alexa. Amazon has also invested more heavily in AI. In November the company said that it was investing an additional $4 billion in the artificial intelligence startup Anthropic. Two months earlier chipmaker Intel said that its foundry business would make some custom artificial intelligence chips for Amazon Web Services, which is Amazon's cloud computing unit and a main driver of its artificial intelligence ambitions. Michelle Chapman, The Associated Press

Nvidia-backed AI startup SandboxAQ creates new data to speed up drug discovery
Nvidia-backed AI startup SandboxAQ creates new data to speed up drug discovery

CTV News

time36 minutes ago

  • CTV News

Nvidia-backed AI startup SandboxAQ creates new data to speed up drug discovery

SAN FRANCISCO — SandboxAQ, an artificial intelligence startup spun out of Alphabet's Google and backed by Nvidia, on Wednesday released a trove of data it hopes will speed up the discovery of new medical treatments by helping scientists understand how drugs stick to proteins. The goal is to help scientists predict whether a drug will bind to its target in the human body. But while the data is backed up by real-world scientific experiments, it did not come from a lab. Instead, SandboxAQ, which has raised nearly US$1 billion in venture capital, generated the data using Nvidia's chips and will feed it back into AI models that it hopes scientists can use to rapidly predict whether a small-molecule pharmaceutical will bind to the protein that researchers are targeting, a key question that must be answered before a drug candidate can move forward. For example, if a drug is meant to inhibit a biological process like the progression of a disease, scientists can use the tool to predict whether the drug molecule is likely to bind to the proteins involved in that process. The approach is an emerging field that combines traditional scientific computing techniques with advancements in AI. In many fields, scientists have long had equations that can precisely predict how atoms combine into molecules. But even for relatively small three-dimensional pharmaceutical molecules, the potential combinations become far too vast to calculate manually, even with today's fastest computers. So SandboxAQ's approach was to use existing experimental data to calculate about 5.2 million new, 'synthetic' three-dimensional molecules - molecules that haven't been observed in the real world, but were calculated with equations based on real-world data. That synthetic data, which SandboxAQ is releasing publicly, can be used to train AI models that can predict whether a new drug molecule is likely to stick to the protein researchers are targeting in a fraction of the time it would take to calculate it manually, while retaining accuracy. SandboxAQ will charge money for its own AI models developed with the data, which it hopes will get results that rival running lab experiments, but virtually. 'This is a long-standing problem in biology that we've all, as an industry, been trying to solve for,' Nadia Harhen, general manager of AI simulation at SandboxAQ, told Reuters on Tuesday. 'All of these computationally generated structures are tagged to a ground-truth experimental data, and so when you pick this data set and you train models, you can actually use the synthetic data in a way that's never been done before.' --- Reporting by Stephen Nellis; Editing by Leslie Adler

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store